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The Lancet is, to the best of our knowledge, the largest study (n=770) in the field of robot-assisted arm training for people with stroke. Recruiting from four UK sites, this pragmatic, three-arm, randomised controlled trial compared robot-assisted training, enhanced upper limb training (EULT; matched in dose and frequency to robot-assisted training), and lower-dose usual care. The population for this study was 770 individuals aged at least 18 years (mean age 61 years [SD 14]; 468 [61%] men) with first-ever stroke (1 week to 5 years before enrolment) with moderate to severe upper limb impairment. The primary outcome was upper limb functional success at the end of the intervention (3 months), measured on the Action Research Arm Test (ARAT). Success was identified a priori, with four distinct success criteria (with improvement cutpoints ranging from 3 to 6 points on the ARAT) that varied according to baseline severity. Although not used previously, this approach aimed to more sensitively capture meaningful change relative to a patient's starting point, which makes sense but needs further validation. An additional strength of the study is that interventions and intervention fidelity were well described. Nor did usual care differ from EULT (aOR 1·51 [98·3% CI 0·90-2·51]). Although some secondary outcome analyses favoured higher-dose training (EULT or robot-assisted training) over usual care, the effects were small. Serious adverse events were few (43 serious adverse events were reported for 39 participants in the robot-assisted training group, 42 were reported for 33 participants in the EULT group, and 29 were reported for 20 participants in the usual care group), none were trial related, and reporting bias is likely because of frequent contact between participants and clinical teams. The cost-utility analysis, not surprisingly, found higher costs for the more intensive treatments (robot-assisted training cost £5387 per participant, EULT cost £4451 per participant, and usual care cost £3785 per participant). Neither robot-assisted training nor EULT would be considered cost-effective at most levels of willingness to pay per quality-adjusted life-year (QALY) worldwide.
The promise of robotics as a powerful tool in the treatment of stroke and brain injury continues to excite stroke survivors, carers, researchers, developers, and funders. RATULS aimed to produce reliable and robust data to progress the field; harmonising treatment protocols, devices, and outcomes, including both functional (ARAT) and activities of daily living (ADL) outcomes. The investigators achieved these goals. The 2018 Cochrane systematic review 3 of robot-assisted arm training, which included 45 trials with 1619 participants, reported significantly improved ADL scores (standardised mean difference [ 
SMD] 0·31 [95% CI 0·09-0·50]) and arm function (SMD 0·32 [0·18-0·46]) at the end of training.
A major caveat, however, was that variations in the intensity, duration, amount, and type of training, device type, participant characteristics, and measurements used across the range of trials included in the metaanalysis add considerable variability and lower evidence quality. RATULS, despite controlling many of these variables, did not show similar benefits in ADL or function over usual care.
The investigators raise some points for consideration in future trials, including the need for better ways of determining the most effective dose of treatment, with dose considerations including length of each session, total number of sessions, and their schedule (sessions per day or week) as well as the intensity of training within a session. In addition to the robotassisted training dose, the investigators question what should be paired with robot-assisted training in future trials to enhance functional outcomes. Although the interventions in this trial were built using best evidence and expert opinion, arguably, the potential for 36 sessions over 3 months of a 45-min dose of robotassisted treatment (or EULT) to deliver substantial changes in function or ADL was low. Meta-analyses suggest much higher doses of training are required to appreciably change outcome. 4 A further point to consider is the time to the start of training after stroke. In RATULS, the median time from stroke to baseline was 240 days (IQR 109-549). In addition to identifying the optimal dose of training to test in future trials, refining the target group for training is crucial and is a recovery research priority. 3 Given the well known non-linear pattern of recovery, individuals at an early phase after stroke are likely to respond differently to those with chronic stroke and associated secondary changes. 5, 6 In the Cochrane review, the treatment effect for patients treated in the first 3 months after stroke with robot-assisted arm training was equal to an SMD of 0·40 (95% CI 0·10 to 0·70) compared with an SMD of 0·19 (-0·13 to 0·50) for patients treated with robot-assisted arm training after 3 months of stroke. 3 Although time since stroke was not a significant factor in RATULS subgroup analyses, the subgroup samples were small and the question remains of who best to target, and when, to optimise outcome.
There are more than ten different devices available for robot-assisted arm therapy. Devices are needed that deliver substantially better functional outcomes than current care. RATULS shows that large, well conducted, multisite trials using one of these devices is possiblelearning from this and getting the fundamentals right for future trials is imperative to advance the field.
